Analysts expect Cytokinetics, Inc. (NASDAQ:CYTK) to post earnings of ($0.48) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Cytokinetics’ earnings, with the lowest EPS estimate coming in at ($0.54) and the highest estimate coming in at ($0.39). Cytokinetics reported earnings of ($0.60) per share during the same quarter last year, which indicates a positive year over year growth rate of 20%. The firm is expected to issue its next quarterly earnings report on Thursday, October 25th.

According to Zacks, analysts expect that Cytokinetics will report full year earnings of ($1.96) per share for the current financial year, with EPS estimates ranging from ($2.17) to ($1.62). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.27) to ($1.58). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Cytokinetics.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, July 26th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, hitting the consensus estimate of ($0.51). The business had revenue of $6.22 million for the quarter, compared to analysts’ expectations of $5.54 million.

CYTK has been the topic of several recent research reports. HC Wainwright upped their target price on shares of Cytokinetics to $24.00 and gave the stock a “buy” rating in a research note on Monday, June 18th. Morgan Stanley downgraded shares of Cytokinetics from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $18.00 to $9.00 in a research report on Wednesday, August 1st. ValuEngine downgraded shares of Cytokinetics from a “hold” rating to a “sell” rating in a research report on Friday, August 3rd. BidaskClub raised shares of Cytokinetics from a “hold” rating to a “buy” rating in a research report on Saturday, July 7th. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $10.00 price objective on shares of Cytokinetics in a research report on Sunday, June 17th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company’s stock. Cytokinetics currently has an average rating of “Hold” and an average target price of $14.00.

In other news, EVP Fady Ibraham Malik sold 3,000 shares of the company’s stock in a transaction on Thursday, June 7th. The shares were sold at an average price of $8.95, for a total value of $26,850.00. Following the completion of the transaction, the executive vice president now owns 96,067 shares in the company, valued at approximately $859,799.65. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Robert I. Blum sold 4,000 shares of the company’s stock in a transaction on Friday, August 3rd. The shares were sold at an average price of $6.65, for a total transaction of $26,600.00. Following the completion of the transaction, the chief executive officer now owns 168,022 shares of the company’s stock, valued at approximately $1,117,346.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,000 shares of company stock valued at $146,780. Company insiders own 5.10% of the company’s stock.

Institutional investors have recently modified their holdings of the company. DRW Securities LLC acquired a new position in shares of Cytokinetics in the 1st quarter valued at $101,000. MetLife Investment Advisors LLC acquired a new position in shares of Cytokinetics in the 4th quarter valued at $153,000. Millennium Management LLC acquired a new position in shares of Cytokinetics in the 4th quarter valued at $218,000. Fox Run Management L.L.C. boosted its holdings in shares of Cytokinetics by 181.8% in the 2nd quarter. Fox Run Management L.L.C. now owns 31,627 shares of the biopharmaceutical company’s stock valued at $263,000 after buying an additional 20,405 shares in the last quarter. Finally, A.R.T. Advisors LLC acquired a new position in shares of Cytokinetics in the 1st quarter valued at $350,000. Institutional investors and hedge funds own 67.54% of the company’s stock.

CYTK traded up $0.05 during trading hours on Friday, hitting $7.00. 210,432 shares of the company’s stock were exchanged, compared to its average volume of 260,321. Cytokinetics has a 12-month low of $6.20 and a 12-month high of $15.95. The company has a market cap of $379.67 million, a P/E ratio of -2.70 and a beta of 1.39. The company has a quick ratio of 7.07, a current ratio of 8.95 and a debt-to-equity ratio of 0.41.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

Further Reading: Google Finance Portfolio Workaround

Get a free copy of the Zacks research report on Cytokinetics (CYTK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.